Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome

References

• Giannuzzi V, Conte R, Landi A, et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis. 2017;12(1):12. .
   PubMedGoogle Scholar
• The European Commission. Communication from the commission—guideline on aspects of the application of article 8(2) of regulation (EC) No 141/2000: review of the period of market exclusivity of orphan medicinal products [Internet]. 2008 [cited 2021 Feb 19. Available from: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:242:0008:0011:EN:PDF.
   Google Scholar
• US Food and Drug Administration. Developing products for rare diseases [internet]. off. comm. 2017 [cited 2021 Feb 19]. p. 8–9. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000%2C207223Orig1s000MedR.pdf.
   Google Scholar
• Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52:3–9.
   PubMedGoogle Scholar
• Scheffer IE, Berkovic S, Capovilla G, et al., ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 58(4): 512–521. 2017. .
   PubMed Web of Science ®Google Scholar
• Nabbout R, Chemaly N, Chipaux M, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8(1):1–8. .
   PubMedGoogle Scholar
• Wang YQ, Fang ZX, Zhang YW, et al. Efficacy of the ketogenic diet in patients with Dravet syndrome: a meta-analysis. Seizure. 2020;81:36–42.
   PubMed Web of Science ®Google Scholar
• Dibué-Adjei M, Fischer I, Steiger HJ, et al. Efficacy of adjunctive vagus nerve stimulation in patients with Dravet syndrome: a meta-analysis of 68 patients. Seizure. 2017;50:p.147–152.
   PubMed Web of Science ®Google Scholar
• Bayat A, Hjalgrim H, Møller RS. The incidence of SCN1A related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia. 2015;56(4):e36–e39.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68(18):e3. .
   PubMedGoogle Scholar
• Lagae L, Brambilla I, Mingorance A, et al., Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey. Dev Med Child Neurol. 60(1): 63–72. 2018. .
   PubMed Web of Science ®Google Scholar
• Losito E, Kuchenbuch M, Chemaly N, et al. Age-related “sleep/nocturnal” tonic and tonic clonic seizure clusters are underdiagnosed in patients with Dravet syndrome. Epilepsy Behav. 2017;74:33–40.
   PubMed Web of Science ®Google Scholar
• Cooper MS, Mcintosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43–47.
   PubMed Web of Science ®Google Scholar
• Tian X, Ye J, Zeng Q, et al. The clinical outcome and neuroimaging of acute encephalopathy after status epilepticus in Dravet syndrome. Dev Med Child Neurol. 2018;60(6):566–573. .
   PubMed Web of Science ®Google Scholar
• Marini C, Scheffer IE, Nabbout R, et al. The genetics of Dravet syndrome. Epilepsia. 2011;52:24–29.
   PubMed Web of Science ®Google Scholar
• Tai C, Abe Y, Westenbroek RE, et al. Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA. 2014;111(30):E3139–48. .
   PubMed Web of Science ®Google Scholar
• Steel D, Symonds JD, Zuberi SM, et al. Dravet syndrome and its mimics: beyond SCN1A. Epilepsia. 2017;58(11):1807–1816. .
   PubMed Web of Science ®Google Scholar
• Knupp KG, Scarbro S, Wilkening G, et al. Parental perception of comorbidities in children with Dravet syndrome. Pediatr Neurol. 2017;76:60–65.
   PubMed Web of Science ®Google Scholar
• Villas N, Meskis MA, Goodliffe S. Dravet syndrome: characteristics, comorbidities, and caregiver concerns. Epilepsy Behav. 2017;74:81–86.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Auvin S, Chiron C, et al. Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome. Epilepsy Behav. 2018;78:232–242.
   PubMed Web of Science ®Google Scholar
• Sinoo C, IML DL, Westers P, et al. Behavior problems and health-related quality of life in Dravet syndrome. Epilepsy Behav. 2019;90:217–227.
   PubMed Web of Science ®Google Scholar
• Skluzacek JV, Watts KP, Parsy O, et al. Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia. 2011;52:95–101.
   PubMed Web of Science ®Google Scholar
• Rodda JM, Scheffer IE, McMahon JM, et al. Progressive gait deterioration in adolescents with Dravet syndrome. Arch Neurol. 2012;69(7):873–878. .
   PubMedGoogle Scholar
• De Liso P, Chemaly N, Laschet J, et al. Patients with Dravet syndrome in the era of stiripentol: a French cohort cross-sectional study. Epilepsy Res. 2016;125:42–46.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54:1595–1604.
   PubMed Web of Science ®Google Scholar
• Möllenhoff K, Bretz F, Dette H. Equivalence of regression curves sharing common parameters. Biometrics Internet. 2020;76:518–529.
   PubMed Web of Science ®Google Scholar
• Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 1705–1717; 2018(59):1705-1717
   Google Scholar
• Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300–308. .
   PubMed Web of Science ®Google Scholar
• Lagae L, Sullivan J, Cross JH, et al. ZX008 (fenfluramine hcl oral solution) in Dravet syndrome: results of a phase 3, randomized, double-blind, placebo-controlled trial [internet]. zogenix.com. 2017. p. 2017. Available from: https://www.zogenix.com/wp-content/uploads/2018/11/AES-ZX008-Study-1.pdf.
   Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–2020. .
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204–e1211.
   PubMed Web of Science ®Google Scholar
• Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(5):613–621. .
   PubMed Web of Science ®Google Scholar
• Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60(2):294–302. .
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50(11):2362–2368. .
   PubMed Web of Science ®Google Scholar
• Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome—comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81–89.
   PubMed Web of Science ®Google Scholar
• Tenney JR, Jain SV. Absence epilepsy: older vs newer AEDs. Curr Treat Options Neurol. 2014;16(5):290.
   PubMed Web of Science ®Google Scholar
• Shi XY, Tomonoh Y, Wang WZ, et al. Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes. Brain Dev. 2016;38(1):40–46. .
   PubMed Web of Science ®Google Scholar
• Takahashi H, Takahashi Y, Mine J, et al. Effectiveness of topiramate in eleven patients with Dravet syndrome. No To Hattatsu. 2010;42(4):273–276.
   PubMedGoogle Scholar
• Coppola G, Capovilla G, Montagnini A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002;49(1):45–48. .
   PubMed Web of Science ®Google Scholar
• Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69(3):250–254. .
   PubMed Web of Science ®Google Scholar
• Lotte J, Haberlandt E, Neubauer B, et al. Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome. Neuropediatrics. 2012;43(1):17–21. .
   PubMed Web of Science ®Google Scholar
• Jacques ER, Alexandridis P. Tablet scoring: current practice, fundamentals, and knowledge gaps. Appl Sci. 2019;9(15):3066.
   Google Scholar
• de Lange IM, Gunning B, Sonsma ACM, et al., Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A related seizure phenotypes. Epilepsia. 59(6): 1154–1165. 2018. .
   PubMed Web of Science ®Google Scholar
• Heger K, Lund C, Larsen Burns M, et al. A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway. Epilepsia Open. 2020;5(3):432–441. .
   PubMedGoogle Scholar
• Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10(1):119–140.
   PubMed Web of Science ®Google Scholar
• Iapadre G, Balagura G, Zagaroli L, et al. Pharmacokinetics and drug interaction of antiepileptic drugs in children and adolescents. Pediatr Drugs. 2018;20(5):429–453. .
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Bouzom F, Hugues C, et al. Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.  Biopharm Drug Dispos. 2017;38(3):209–230.
   Google Scholar
• Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52(8):627–645.
   PubMed Web of Science ®Google Scholar
• Saruwatari J, Ogusu N, Shimomasuda M, et al. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and n-desmethylclobazam in Japanese patients with epilepsy. Ther Drug Monit. 2014;36(3):302–309. .
   PubMed Web of Science ®Google Scholar
• FDA (Food and Drug Administration). Drug Approval Package: onfi NDA number 202067 [Internet]. 2011 [cited 2020 Sep 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000TOC.cfm.
   Google Scholar
• Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs. 2006;66(14):1817–1829.
   Google Scholar
• Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39(5):508–512. .
   PubMed Web of Science ®Google Scholar
• Nguyen Thanh T, Chiron C, Dellatolas G, et al. Efficacité et tolérance à long terme du stiripentol dans le traitement de l’épilepsie myoclonique sévère du nourrisson (syndrome de Dravet). Arch Pediatr. 2002;9(11):1120–1127. .
   PubMedGoogle Scholar
• Brunklaus A, Ellis R, Reavey E, et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135(8):2329–2336. .
   PubMedGoogle Scholar
• Mueller A, Boor R, Coppola G, et al. Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome. Epilepsy Behav. 2011;21(3):282–284. .
   PubMed Web of Science ®Google Scholar
• Uldall P, Bulteau C, Pedersen SA, et al. Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res. 2000;42(2–3):159–168. .
   PubMed Web of Science ®Google Scholar
• Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 2000;22(2):75–80.
   PubMed Web of Science ®Google Scholar
• Chipaux M, Villeneuve N, Sabouraud P, et al. Unusual consequences of status epilepticus in Dravet syndrome. Seizure. 2010;19(3):190–194. .
   PubMed Web of Science ®Google Scholar
• Saito Y, Oguni H, Awaya Y, et al. Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy. Neuropediatrics. 2001;32(5):231–235. .
   PubMed Web of Science ®Google Scholar
• Franco V, Canevini MP, Capovilla G, et al. Off-label prescribing of antiepileptic drugs in pharmacoresistant epilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy. CNS Drugs. 2014;28(10):939–949. .
   PubMed Web of Science ®Google Scholar
• Kuchenbuch M, Chemaly N, Henniene KM, et al. Off-label use and manipulations of antiepileptic drugs in children: analysis of the outpatient prescriptions in a tertiary center. Epilepsy Behav. 2018;82:133–139.
   PubMed Web of Science ®Google Scholar
• Bellis JR, Kirkham JJ, Thiesen S, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med. 2013;11(1):238. .
   PubMedGoogle Scholar
• Turner S, Nunn A, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 2007;88(9):965–968. .
   Google Scholar
• Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. The Lancet. 2019;394(10216):2243–2254. .
   PubMed Web of Science ®Google Scholar
• US food and drug administration. FDA approves new indication for drug containing an active ingredient derived from cannabis to treat seizures in rare genetic disease [internet]. FDA NEWS RELEASE. [cited 2021 Feb 19]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare
   Google Scholar
• Ceulemans B. Overall management of patients with Dravet syndrome. Dev Med Child Neurol. 2011;53:19–23.
   PubMed Web of Science ®Google Scholar
• Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52:72–75.
   PubMedGoogle Scholar
• Chiron C. Stiripentol. Neurotherapeutics. 2007;4:123–125.
   Google Scholar
• Fisher JL. Interactions between modulators of the GABAA receptor: stiripentol and benzodiazepines. Eur J Pharmacol. 2011;654(2):160–165.
   PubMed Web of Science ®Google Scholar
• Auvin S, Lecointe C, Dupuis N, et al. Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain. Epilepsia. 2013;54(12):2082–2090.
   PubMed Web of Science ®Google Scholar
• Sada N, Lee S, Katsu T, et al. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347(80–):1362–1367.
   PubMedGoogle Scholar
• Peigné S, Chhun S, Tod M, et al. Population pharmacokinetics of stiripentol in paediatric patients with Dravet syndrome treated with stiripentol, valproate and clobazam combination therapy. Clin Pharmacokinet. 2018;57(6):739–748.
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Ratnaraj N, Patsalos PN, et al. Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis. Epilepsia. 2006;47(11):1841–1854.
   PubMed Web of Science ®Google Scholar
• Morrison G, Crockett J, Blakey G, et al. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(8):1009–1031.
   PubMed Web of Science ®Google Scholar
• Boyd B, Smith S, Gammaitoni A, et al. A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther. 2019;57(1):11–19.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Takahashi Y, Imai K, et al. Effect of CYP inducers/inhibitors on topiramate concentration: clinical value of therapeutic drug monitoring. Ther Drug Monit. 2017;39(1):55–61.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Stiripentol: a review in Dravet syndrome. Drugs. 2019;79(16):1785–1796.
   PubMed Web of Science ®Google Scholar
• Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. The Lancet. 2000;356(9242):1638–1642.
   PubMed Web of Science ®Google Scholar
• Center for drug evaluation and research. Application number: 206709Orig1s000 & 207223Orig1s000 [Internet]. Clin. Rev. 2018 [cited 2020 Sep 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000%2C207223Orig1s000MedR.pdf
   Google Scholar
• Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017;135(1):73–79.
   PubMed Web of Science ®Google Scholar
• US food and drug administration. FDA approves new therapy for rare disease affecting optic nerve, spinal cord [Internet]. FDA Press Announc. [cited 2020 Sep 29]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-rare-disease-affecting-optic-nerve-spinal-cord
   Google Scholar
• Committee for medicinal products for human use (European medicine agency). Fintepla-fenfluramine [internet]. EMA/CHMP/510338/2020. 2020 [cited 2020 Nov 10]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fintepla_en.pdf.
   Google Scholar
• Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol. 2017;8:191.
   PubMed Web of Science ®Google Scholar
• Lai WW, Galer BS, Wong PC, et al. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020;61(11):16638
   Web of Science ®Google Scholar
• Li R, Serdula MK, Williamson DF, et al. Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy. Int J Obes. 1999;23(9):926–928. .
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131–1139. .
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Schoonjans A, Marchau F, et al. Five‐year extended follow‐up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57(7):e129–e134. .
   PubMed Web of Science ®Google Scholar
• Gray RA, Stott CG, Jones NA, et al. Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent. Cannabis Cannabinoid Res. 2020;5(2):145–149. .
   PubMedGoogle Scholar
• Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22:S10–S15.
   PubMed Web of Science ®Google Scholar
• Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60(8):1586–1592. .
   PubMed Web of Science ®Google Scholar
• Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16:9–29.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Zaccara G, Russo E, et al. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. Expert Rev Neurother. 2021;21(1):99–110. .
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Szaflarski JP, Gidal B, et al. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. Epilepsia. 2020;61(9):1854–1868. .
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Brigo F, Trinka E, et al. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34(3):229–241. .
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, Kuchenbuch M, Hachon-Le Camus C, et al. Slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study. Front Neurol. 2020;11:829.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Thiele EA, Wright S, et al. Cannabidiol efficacy independent of clobazam: meta-analysis of four randomized controlled trials. Acta Neurol Scand. 2020;142(6):531–540. .
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61(6):1090–1098. .
   PubMed Web of Science ®Google Scholar
• Rosenberg EC, Louik J, Conway E, et al. Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. 2017;58(8):e96–e100. .
   PubMed Web of Science ®Google Scholar
• Romoli M, Mazzocchetti P, D’Alonzo R, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2018;17:926–946.
   Web of Science ®Google Scholar
• Valproic acid drug interactions - drugs.com [internet]. [cited 2020 Sep 29]. Available from: https://www.drugs.com/drug-interactions/valproic-acid.html. Access date: Feburary 19th,2021
   Google Scholar
• Wheless JW, Fulton SP, Mudigoudar BD. Dravet syndrome: a review of current management. Pediatr Neurol. Elsevier Inc. 2020;107:28–40.
   PubMed Web of Science ®Google Scholar
• tze NY, Collins SD. Clobazam. Neurotherapeutics. 2007;4(1):138–144.
   PubMed Web of Science ®Google Scholar
• Doi T, Ueda Y, Tokumaru J, et al. Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe+++-induced epileptic rats. Mol Brain Res. 2005;142(2):91–96. .
   PubMedGoogle Scholar
• Yamamoto Y, Takahashi Y, Imai K, et al. Influence of cyp2c19 polymorphism and concomitant antiepileptic drugs on serum clobazam and n-desmethyl clobazam concentrations in patients with epilepsy. Ther Drug Monit. 2013;35(3):305–312. .
   PubMed Web of Science ®Google Scholar
• Kouga T, Shimbo H, Iai M, et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome. Brain Dev. 2015;37(2):243–249. .
   PubMed Web of Science ®Google Scholar
• Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia.2019;60:2224–2234.
   PubMed Web of Science ®Google Scholar
• Redondo P, Vicente J, España A, et al. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol. 1996;135(6):999–1002.
   PubMed Web of Science ®Google Scholar
• Jensen HS, Nichol K, Lee D, et al. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α2- versus α1-GABAa-receptor complexes. PLoS One. 2014;9(2):1–8. .
   Web of Science ®Google Scholar
• Mao X, Ji C, Sun C, et al. Topiramate attenuates cerebral ischemia/reperfusion injury in gerbils via activating GABAergic signaling and inhibiting astrogliosis. Neurochem Int. 2012;60(1):39–46. .
   PubMed Web of Science ®Google Scholar
• Glauser TA. Topiramate. Epilepsia. 1999;40(s5):s71–s80.
   PubMedGoogle Scholar
• Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin. Ther. Excerpta Medica Inc. 1997;19(6):1294–1308.
   Google Scholar
• Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9(8):590–594. .
   PubMed Web of Science ®Google Scholar
• Kröll-Seger J, Portilla P, Dulac O, et al. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006;37(6):325–329. .
   PubMed Web of Science ®Google Scholar
• Albsoul-Younes AM, Salem HA, Ajlouni SF, et al. Topiramate slow dose titration: improved efficacy and tolerability. Pediatr Neurol. Elsevier. 2004;31(5):349–352. .
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle is the protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101(26):9861–9866. .
   PubMed Web of Science ®Google Scholar
• Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136(5):659–672. .
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Baftiu A, Tysse I, et al. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther Drug Monit. 2012;34(4):440–445. .
   PubMed Web of Science ®Google Scholar
• Chhun S, Troude P, Villeneuve N, et al. A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target. Seizure. 2011;20(4):320–325. .
   PubMed Web of Science ®Google Scholar
• Egunsola O, Choonara I, Sammons HM. Safety of levetiracetam in paediatrics: a systematic review. PLoS One. 2016;11(3):149686.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Doi T, Tokumaru J, et al. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Mol Brain Res. 2003;116(1–2):1–6. .
   PubMedGoogle Scholar
• Wallander KM, Ohman I, Dahlin DM. Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy. Neuropediatrics. 2014;45(6):362–370.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Rosati A, Segieth J, et al. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia. 2013;54(8):1473–1480. .
   PubMed Web of Science ®Google Scholar
• Oguni H, Hayashi K, Oguni M, et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia. 1994;35(6):1140–1145. .
   PubMed Web of Science ®Google Scholar
• Crunelli V, Leresche N. Block of thalamic t-type ca2+ channels by ethosuximide is not the whole story. Epilepsy Curr. 2002;2(2):53–56.
   PubMedGoogle Scholar
• Shalomov B, Dabbah S, Dascal N. Antiepileptic drug ethosuximide may regulate absence seizures through different ion channels. Biophys J. 2020;118(3):588a.
   Web of Science ®Google Scholar
• Czerniak E, Oberlander TF, Weimer K, et al. “Placebo by proxy” and “nocebo by proxy” in children: a review of parents’ role in treatment outcomes. Front Psychiatry. 2020;11:11.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Kuchenbuch M. Impact of predictive, preventive and precision medicine strategies in epilepsy. Nat Rev Neurol. 2020;16::674–688.0.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Auvin S, Chiron C, et al. Perception of impact of Dravet syndrome on children and caregivers in multiple countries: looking beyond seizures. Dev Med Child Neurol. 2019;61(10):1229–1236.
   PubMed Web of Science ®Google Scholar
• Liau G, Christiansen A, Han Z. TANGO oligonucleotides for the treatment of Dravet syndrome: safety, biodistribution, and pharmacology in the non-human primate. AES Annu Meet. Internet]. 2019 [cited 2021 Feb 19]. Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2421641
   Google Scholar
• Hsiao J, Yuan TY, Tsai MS, et al. Upregulation of haploinsufficient gene expression in the brain by targeting a long non-coding RNA improves seizure phenotype in a model of Dravet syndrome. EBioMedicine. 2016;9:257–277.
   PubMed Web of Science ®Google Scholar
• Young A, Tanenhaus A, Belle AAGAB. A-selective AAV vector upregulates endogenous SCN1A expression and reverses multiple phenotypes in a mouse model of Dravet syndrome. AES Annu Meet. Internet]. 2019 [2021 Feb 19]. p. Abstract 3.1. Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2421999
   Google Scholar
• Colasante G, Lignani G, Brusco S, et al. dCas9-based scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice. Mol Ther. 2019;28(1):235–253. .
   PubMed Web of Science ®Google Scholar